TY - JOUR
T1 - Preventing heart failure
T2 - a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology
AU - Piepoli, Massimo F
AU - Adamo, Marianna
AU - Barison, Andrea
AU - Bestetti, Reinaldo B
AU - Biegus, Jan
AU - Böhm, Michael
AU - Butler, Javed
AU - Carapetis, Jonathan
AU - Ceconi, Claudio
AU - Chioncel, Ovidiu
AU - Coats, Andrew
AU - Crespo-Leiro, Maria G
AU - de Simone, Giovanni
AU - Drexel, Heinz
AU - Emdin, Michele
AU - Farmakis, Dimitros
AU - Halle, Martin
AU - Heymans, Stephane
AU - Jaarsma, Tiny
AU - Jankowska, Ewa
AU - Lainscak, Mitja
AU - Lam, Carolyn S P
AU - Løchen, Maja-Lisa
AU - Lopatin, Yuri
AU - Maggioni, Aldo
AU - Matrone, Benedetta
AU - Metra, Marco
AU - Noonan, Katharine
AU - Pina, Ileana
AU - Prescott, Eva
AU - Rosano, Giuseppe
AU - Seferovic, Petar M
AU - Sliwa, Karen
AU - Stewart, Simon
AU - Uijl, Alicia
AU - Vaartjes, Ilonca
AU - Vermeulen, Roel
AU - Monique Verschuren, W M
AU - Volterrani, Maurizio
AU - von Heahling, Stephan
AU - Hoes, Arno
N1 - Funding Information:
M.B. reports fees from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Medtronic, Novartis, ReCor, Servier, and Vifor and is supported by the Deutsche Forschungsgemeinschaft (DFG, TTR 219, S‐01, project ID 322900939). M.G.C.‐L. received research grants to my institution and personal fees for lectures or advisory board meetings from CIBERCV. Novartis, AstraZeneca, Vifor, Pfizer, Astellas Pharma. None of them related to the present manuscript. S.H. has received personal fees for scientific advice to AstraZeneca, Cellprothera, and Merck; unrestricted research grant from Pfizer. C.S.P.L. is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Boston Scientific, Bayer, Roche Diagnostics, AstraZeneca, Medtronic, and Vifor Pharma; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Abbott Diagnostics, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Biofourmis, Boehringer Ingelheim, Boston Scientific, Corvia Medical, Cytokinetics, Darma Inc., Us2.ai, JanaCare, Janssen Research & Development LLC, Medtronic, Menarini Group, Merck, MyoKardia, Novartis, Novo Nordisk, Radcliffe Group Ltd, Roche Diagnostics, Sanofi, Stealth BioTherapeutics, The Corpus, Vifor Pharma, and WebMD Global LLC; and serves as co‐founder and non‐executive director of Us2.ai. A.M. received personal fees for the participation in committees of studies sponsored by Bayer, Fresenius, Novartis outside the present work. M.F.P. received research grants to his institution and personal fees for lectures or advisory board meetings from Novartis, Vifor, AstraZeneca, and CHF solution. None of them related to the present manuscript. P.M.S. received Medtronic honorarium for lecture, Abbott honorarium for lecture, Servier honorarium for lecture, Astra Zeneca honorarium for lecture, Respicardia honorarium for lecture, Boehringer Ingelheimconsultancy agreement and honorarium for lecture, Novartis consultancy agreement and honorarium for lecture, Vifor Pharma consultancy agreement. All other authors declared no conflict of interest. Conflict of interest:
Publisher Copyright:
The article has been co-published with permission in the European Journal of Preventive Cardiology and European Journal of Heart Failure. All rights reserved. © the Author(s) 2022. The articles are identical except for minor stylistic and spelling differences in keeping with each journal's style. Either citation can be used when citing this article.
PY - 2022/1
Y1 - 2022/1
N2 - The heart failure epidemic is growing and its prevention, in order to reduce associated hospital readmission rates and its clinical and economic burden, is a key issue in modern cardiovascular medicine. The present position paper aims to provide practical evidence-based information to support the implementation of effective preventive measures. After reviewing the most common risk factors, an overview of the population attributable risks in different continents is presented, to identify potentially effective opportunities for prevention and to inform preventive strategies. Finally, potential interventions that have been proposed and have been shown to be effective in preventing heart failure are listed.
AB - The heart failure epidemic is growing and its prevention, in order to reduce associated hospital readmission rates and its clinical and economic burden, is a key issue in modern cardiovascular medicine. The present position paper aims to provide practical evidence-based information to support the implementation of effective preventive measures. After reviewing the most common risk factors, an overview of the population attributable risks in different continents is presented, to identify potentially effective opportunities for prevention and to inform preventive strategies. Finally, potential interventions that have been proposed and have been shown to be effective in preventing heart failure are listed.
UR - http://www.scopus.com/inward/record.url?scp=85123644764&partnerID=8YFLogxK
U2 - 10.1002/ejhf.2351
DO - 10.1002/ejhf.2351
M3 - Review article
C2 - 35083829
SN - 1388-9842
VL - 24
SP - 143
EP - 168
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
IS - 1
ER -